about
Clinical epidemiological analysis of the relationship between pancreatic cancer and diabetes mellitus: data from a single institution in China.Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.Decreased serum CA19-9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux-en-Y gastric bypass.Tumor markers as a diagnostic key for hilar cholangiocarcinoma.Markers of bile duct tumorsSerum CA19-9 level associated with metabolic control and pancreatic beta cell function in diabetic patients.Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration.Carbohydrate 19.9 antigen serum levels in liver disease.Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection?The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.Association between serum CA 19-9 and metabolic syndrome: A cross-sectional study.Serum CA 19-9 and risk of incident diabetes in middle-aged and elderly Chinese: a prospective cohort study.Colorectal carcinoma with extremely low CA19-9.Reversible high blood CEA and CA19-9 concentrations in a diabetic patient.Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes.Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT.Smoking and serum CA19-9 levels according to Lewis and secretor genotypes.The effect of glycemic control on CEA, CA 19-9, amylase and lipase levels.Clinical implication of elevated CA 19-9 level and the relationship with glucose control state in patients with type 2 diabetes.Relationship between CA 19-9 levels and glucose regulation in a middle-aged and elderly Chinese population.Survival and glycemic control outcomes among patients with coexisting pancreatic cancer and diabetes mellitus.
P2860
Q33411513-2D62359B-667D-417F-971B-D1B9B0F4F331Q33684453-61762D16-D443-4019-A576-2F4CBFA96D53Q34523725-E046B0FD-C117-435D-B1D1-51CBA0EE3793Q34624362-2DD36649-BCBF-4AC7-90BF-CD3F0522C791Q34628852-83A98995-48CC-4605-B42A-081133B778B5Q36063547-32409C34-A606-461B-BDCF-54E76A644FFCQ37157579-D8C8EC2E-5002-421C-9E28-A463F74E1CA6Q37299982-41072E67-3BFD-4F8A-BCE9-48A25F7FFDF7Q37563998-3BFBA13E-A523-4D7E-969F-3DA0918FCF63Q37868446-492D44E5-96D8-4BD5-BDE7-905F3B5B851FQ39032211-D1C97EC5-A52E-4856-AE25-958B95F42897Q39225299-E784525F-0C84-48A1-A18D-A141CF1F63B2Q42037964-39CA2EFC-A1C9-4455-9FE1-809593A4236CQ42405453-A3D760C6-527E-44E3-81E0-00AA8B3BA561Q43154547-52F758B3-457C-4B86-8223-B39C06B538D0Q45760824-BF4631DF-F88E-4DDA-83A5-2769E835315EQ46358023-96E38EAA-C517-4B2D-9813-5DEA3D9C4683Q51315812-AE0D7EBF-FC70-4815-9910-AF8645D242BAQ51332951-833F716F-DE88-46D3-841D-2E24CB96ABBEQ51363849-F20C54DC-A1CE-4A62-AA40-48D08031E2A7Q55267419-1D5FF454-5EC9-4F07-A3B0-B4512BD3F7C5
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Type 2 diabetes mellitus and CA 19-9 levels.
@ast
Type 2 diabetes mellitus and CA 19-9 levels.
@en
Type 2 diabetes mellitus and CA 19-9 levels.
@nl
type
label
Type 2 diabetes mellitus and CA 19-9 levels.
@ast
Type 2 diabetes mellitus and CA 19-9 levels.
@en
Type 2 diabetes mellitus and CA 19-9 levels.
@nl
prefLabel
Type 2 diabetes mellitus and CA 19-9 levels.
@ast
Type 2 diabetes mellitus and CA 19-9 levels.
@en
Type 2 diabetes mellitus and CA 19-9 levels.
@nl
P2093
P2860
P356
P1476
Type 2 diabetes mellitus and CA 19-9 levels.
@en
P2093
Alpaslan Mayadagli
Can Dolapcioglu
Ekrem Orbay
Gamze Kilicoglu
Mehmet Sargin
Oya Uygur-Bayramicli
Resat Dabak
Yuksel Guleryuzlu
P2860
P304
P356
10.3748/WJG.V13.I40.5357
P407
P577
2007-10-01T00:00:00Z